Key facts
- It has raised $97.9M; the latest was Early Stage VC ($86.7M) in Dec 2024.
- Notable investors include GV, F-Prime Capital, ARCH Venture Partners, Novartis Venture Fund, BioGeneration Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Rhygaze
- ·The full record, as it builds
Funding rounds
No funding rounds for Rhygaze are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Rhygaze
Developer of novel gene therapy designed to restore vision in patients. The company's therapy technology delivers a light-sensor gene specifically to cone cells that have lost light sensitivity, and repair their ability to detect light, enabling the healthcare industry to provide vision restoration for patients suffering from blindness.
- Sector
- Healthcare
- HQ
- Basel, Switzerland
- Founded
- 2024
- Employees
- 5
- Website
- rhygaze.com/
- Ownership
- Privately Held (backing)
Rhygaze doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rhygaze shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rhygaze in its N-PORT filings yet. We sweep new filings monthly.